Peter Powchik
Nessuna posizione attualmente
Patrimonio netto: 161 940 $ in data 31/03/2024
Profilo
Peter Powchik's former jobs include being a Senior Medical Director at Sumitomo Pharma America, Inc., a Principal at Pfizer Inc., a VP-Clinical Development & Medical Affairs at Novartis Pharmaceuticals Corp., a Chief Medical Officer & Senior Vice President at Chugai Pharma USA LLC, and a Senior Vice President-Clinical Development at Regeneron Pharmaceuticals, Inc. He also served as the Global Scientific Director, Director & EVP at Vaxxinity, Inc. from 2023 to 2024.
Dr. Powchik obtained a doctorate degree from New York University School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
VAXXINITY INC CLASS A
0.20% | 02/10/2023 | 225 858 ( 0.20% ) | 161 940 $ | 31/03/2024 |
Precedenti posizioni note di Peter Powchik
| Società | Posizione | Fine |
|---|---|---|
| VAXXINITY, INC. | Chief Tech/Sci/R&D Officer | 31/03/2024 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2018 |
Chugai Pharma USA LLC
 Chugai Pharma USA LLC Medical DistributorsDistribution Services Part of Roche Holding AG, Chugai Pharma USA LLC is a private company that develops safe and effective drugs. The company is based in Bedminster, NJ. | Chief Tech/Sci/R&D Officer | 01/10/2006 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Chief Tech/Sci/R&D Officer | 01/05/2005 |
| PFIZER, INC. | Corporate Officer/Principal | 01/04/2001 |
Formazione di Peter Powchik
| New York University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| VAXXINITY, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Chugai Pharma USA LLC
Chugai Pharma USA LLC Medical DistributorsDistribution Services Part of Roche Holding AG, Chugai Pharma USA LLC is a private company that develops safe and effective drugs. The company is based in Bedminster, NJ. | Distribution Services |
| Chugai Pharma USA, Inc. |
- Borsa valori
- Insiders
- Peter Powchik
